Nextech3D.AI Expanding AI Patent Portfolio and Announces Six New 3D Modeling Contracts & Renewals
January 09, 2024 10:32 ET
|
Nextech3D.ai
TORONTO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via IBN -- Nextech3D.AI (OTCQX: NEXCF) (CSE: NTAR) (FSE: 1SS), an AI-3D model supplier for major e-commerce retailers announces an uptick in sales with a...
Spaceback Social CTV Brings the Power of Social Media Content to CTV Advertising
September 28, 2023 09:00 ET
|
Spaceback
Spaceback, the leading creative automation platform announced its new offering: Social CTV. CB2 pilots the new offering to bring social media posts to CTV.
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
May 13, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022Corbus...
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
March 15, 2021 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
●Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 ●Company focused on advancing in-house programs in metabolic diseases, fibrotic disorders, and cancer with...
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
March 08, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
• Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET Norwood, MA, March 08, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)...
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
June 29, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two years in the lenabasum Phase 2 open-label...
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
June 01, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020 Norwood, MA, June ...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
May 15, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 15, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
May 04, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Management to host conference call and webcast on Monday, May 11 at 8:30 a.m. ET- NORWOOD, MA, May 04, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...
Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
February 11, 2020 16:01 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...